SUNDAY 10 OCTOBER 2021

Sunday 10 Oct

08:00

Sponsored Integrated Symposium 4

More information on www.timm2021.org/sponsored-symposia

14:15

Parallel Symposia 14-17

Symposium 14 Fungal respiratory infections in Cystic Fibrosis

Chairs: Jean-Philippe Bouchara, France & Michaela Lackner, Austria, FECMM

14:15

S14.1 Fungal respiratory infections in Cystic Fibrosis

Michaela Lackner, Austria, FECMM

14:35

S14.2 Exophiala dermatitidis in cystic fibrosis

Jörg Steinmann, Germany, FECMM

14:55

S14.3 Immunotherapy

Darius Armstrong-James, United Kingdom, FECMM

15:15

S14.4 Genotypic and phenotypic portrait of Candida albicans clinical isolates colonizing the airways of patients with cystic fibrosis

Mayssa Gnaien, Tunisia

15:30

S14.5 Exophiala dermatitidis infection in Cystic Fibrosis accelerates lung function decline; a retrospective single-centre review of historical lung function

Jonathan Ayling-smith, United Kingdom

Symposium 15 Cryptococosis: From bench to bedside

Chairs: Valentina Arsic Arsenijevic, Serbia, FECMM & Tom Harrison, United Kingdom

14:15

S15.1 Cryptococcus qPCR assays: the future for routine mycology labs and clinical trials dealing with cryptococcosis – An AMBITION sub-study

Alexandre Alanio, France, FECMM

14:35

S15.2 AMBITION trial and beyond

Joe Jarvis, United Kingdom

14:55

S15.3 Titan cells in cryptococcosis

Liz Ballou, United Kingdom

15:15

S15.4 Modifications of the cell wall in cryptococcosis

Liliane Mukaremera, United Kingdom

15:35

S15.5 Molecular analysis of Cryptococcus spp. reveals species diversity and Multilocus Sequence Typing heterogeneity among people living with HIV in Kinshasa

Bive Zono, Congo

Symposium 16 Azoles, Echinocandins and Polyenes strenghts and weaknesses

Chairs: Gordon Ramage, United Kingdom, FECMM & Marika Jürna-Ellam, Estonia

14:15

S16.1 Azoles

Roger Brüggemann, the Netherlands, FECMM

14:35

S16.2 Echinocandins

Andrej Spec, USA, FECMM

14:55

S16.3 Managing antifungal tolerant biofilms: our current understanding and future directions

Gordon Ramage, United Kingdom, FECMM

15:15

S16.4 Breakthrough infections - Definitions, Epidemiology and Outcomes

Jeff Jenks, USA

15:25

S16.5 Ibrexafungerp is effective in treating murine mucormycosis caused by Rhizopus delemar

Ashraf Ibrahim, United States

15:35

S16.6 Lanosterol 14-alpha-demethylase-F5 homologue mediates short-tailed azole resistance in mucormycetes: Characterization of Mucor circinelloides LDM-genes in the heterologous model S. cerevisiae

Katharina Rosam, Austria

Symposium 17 Management of immunoallergic fungal diseases

Chairs: Tom Rogers, Ireland & Jean-Pierre Gangneux, France, FECMM

14:15

S17.1 Antifungal treatment in kids with allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization : where do we stand?

Adilia Warris, United Kingdom, FECMM

14:35

S17.2 severe asthma and the role of aspergillis

Peter Cook, United Kingdom

14:55

S17.3 Impact of environmental approaches for allergen avoidance and asthma control

Jean-Pierre Gangneux, France, FECMM

15:15

S17.4 Type 2-high asthma patients reveal a specific indoor mycobiome and microbiome

Laurence Delhaes, French Guiana

15:30

S17.5 Antifungal therapeutic outcomes in Allergic Bronchopulmonary Aspergillosis (ABPA) patients with asthma

Lisa Nwankwo, United Kingdom

15:45

Coffee break

16:15

Parallel Symposia 18-21

Symposium 18 Diagnosis of invasive aspergillosis: What is new?

Chairs: Lewis White, UK, FECMM & Petr Hamal, Czech Republic, FECMM

16:15

S18.1 Multicenter evaluation of the VirClia galactomannan assay on bronchoalveolar lavage fluid from patients with hematological malignancies

Jochem Buil, the Netherlands

16:35

S18.2 Point-of-care testing

Juergen Prattes, Austria, FECMM

16:55

S18.3 PCR Diagnosis

Lewis White, United Kingdom, FECMM

17:15

S18.4 Urine Aspergillus Antigen Detection as an Aid to Diagnose Invasive Aspergillosis

Kieren Marr, USA

17:25

S18.5 Proteomic Analysis of Humoral Immune Components in Bronchoalveolar Lavage of Patients Infected or Colonized by Aspergillus fumigatus

Sarah Dellière, France

17:35

S18.6 Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19 Associated Pulmonary Aspergillosis (CAPA): A multicenter study

Brice Autier, France

Symposium 19 Pre clinical anti fungal studies

Chairs: Alexandra Brand, United Kingdom & Mihai Mares, Romania, FECMM

16:15

S19.1 Antifungal tolerance: spanning the genetic and phenotypic diversity of Candida albicans

Judy Berman, Israel

16:35

S19.2 Paradoxical growth

Carol Munro, United Kingdom

16:55

S19.3 BET bromodomain inhibition as a potential new antifungal therapeutic strategy

Jérôme Govin, France

17:15

S19.4 Use of animal infection models in preclinical antifungal development

David Andes, USA, FECMM

17:35

S19.5 Development of the Arabian killifish (Aphanius dispar) as a model host to study human fungal pathogens.

Mark Ramsdale, United Kingdom

Symposium 20 Improving outcomes for patients with invasive fungal infection in routine care in LMIC

Chairs: Rita Oladele, Nigeria, FECMM & Tom Harrison, United Kingdom

16:15

S20.1 From trials to routine care - strengthening pathways to effective implementation – lessons from cryptococcal meningitis and the UNITAID/CHAI programme for advanced HIV disease

Angela Loyse, United Kingdom

16:35

S20.2 CDC Mycology Branch programme to support diagnosis and treatment in LMIC

Tom Chiller, USA

16:55

S20.3 Improving outcomes for patients with sporotrichosis, chromoblastomycosis and mycetoma in South America

Flavio Queiros Telles, Brazil

17:15

S20.4 Mycology Expereince from a Cancer Hospital in Pakistan

Summiya Nizamuddin, Pakistan

17:30

S20.5 Laboratory diagnosis of invasive fungal infections in a low-resource setting: a five year retrospective study

Rebecca Peters, Nigeria

Symposium 21 Invasive fungal infections in special populations

Chairs: Volkan Özenci, Sweden & Silke Schelenz, United Kingdom, FECMM

16:15

S21.1 Neonatal candiasis

Tom Walsh, USA, FECMM

16:35

S21.2 ECMO and dialysis

Robert Krause, Austria, FECMM

16:55

S21.3 Obese patients

Roger Brüggemann, the Netherlands, FECMM

17:15

S21.4 NEOGLUCAN study: Serial (1–3) beta D Glucan levels in high risk neonates

Laura Ferreras-Antolin, United Kingdom

17:30

S21.5 Optimization of fluconazole therapy for the treatment of invasive candidiasis in preterm infants

Aline Engbers, the Netherlands

18:00